The Sofia 2 Flu + SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from influenza A and influenza B, and SARS-CoV-2. The Sofia 2 Flu + SARS Antigen FIA with the Sofia 2 analyzer provides automated and objective results in 15 minutes, allowing for testing of patients suspected of influenza A, influenza B, and COVID-19/2019-nCoV at the Point of Care.
Time savings, material conservation, and patient comfort.
Rapid results to support efficient diagnosis of patients.
Reliable results without cross-reactivity to seasonal coronaviruses.
Adjusts to your volume fluctuations. Allows for significant throughput and batching of samples in READ NOW Mode.
Seamless test workflow follows a similar format to CLIA-waived Sofia and Sofia 2 assays.
Provides automated tracking, data capture, government reporting, and exclusive disease mapping.
Objective result that eliminates the subjectivity of a visual result.
Ready for use with Sofia 2 for nasal or nasopharyngeal swab procedure.
